Aclaris Therapeutics, Inc. (ACRS)
6.54
+0.23
(+3.65%)
USD |
NASDAQ |
Aug 25, 16:00
6.65
+0.11
(+1.68%)
After-Hours: 18:47
Aclaris Therapeutics Debt to Equity Ratio : 0.0149 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0148 |
| March 31, 2026 | 0.0138 |
| December 31, 2025 | 0.0205 |
| September 30, 2025 | 0.0187 |
| June 30, 2025 | 0.018 |
| March 31, 2025 | 0.0172 |
| December 31, 2024 | 0.0167 |
| September 30, 2024 | 0.0208 |
| June 30, 2024 | 0.021 |
| March 31, 2024 | 0.0245 |
| December 31, 2023 | 0.0223 |
| September 30, 2023 | 0.0137 |
| June 30, 2023 | 0.0131 |
| March 31, 2023 | 0.0146 |
| December 31, 2022 | 0.0114 |
| September 30, 2022 | 0.0108 |
| June 30, 2022 | 0.0109 |
| March 31, 2022 | 0.0152 |
| December 31, 2021 | 0.0147 |
| September 30, 2021 | 0.0141 |
| June 30, 2021 | 0.0596 |
| March 31, 2021 | 0.1251 |
| Date | Value |
|---|---|
| December 31, 2020 | 0.3758 |
| September 30, 2020 | 0.3498 |
| June 30, 2020 | 0.2924 |
| March 31, 2020 | 0.251 |
| December 31, 2019 | 0.0602 |
| September 30, 2019 | 0.4036 |
| June 30, 2019 | 0.2615 |
| March 31, 2019 | 0.1862 |
| December 31, 2018 | 0.1397 |
| September 30, 2018 | 0.004 |
| June 30, 2018 | 0.0032 |
| March 31, 2018 | 0.0007 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Corcept Therapeutics, Inc. | 0.0133 |
| Nektar Therapeutics | 0.1505 |
| Xeris Biopharma Holdings, Inc. | -29.74 |
| Crinetics Pharmaceuticals, Inc. | 0.0396 |
| Alumis, Inc. | 0.0806 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 179.69M |
| Total Liabilities (Quarterly) | 55.11M |
| Shareholders Equity (Quarterly) | 124.58M |
| Current Ratio | 3.462 |
| Net Debt Paydown Yield | 0.02% |